» Articles » PMID: 35002214

Tissue Plasminogen Activator Rescues Steroid-induced Outflow Facility Reduction Via Non-enzymatic Action

Overview
Journal Mol Vis
Date 2022 Jan 10
PMID 35002214
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Tissue plasminogen activator (tPA) prevents steroid-induced reduction in aqueous humor outflow facility; however, its mechanism of action at the trabecular meshwork (TM) remains unclear. Enzymatic and non-enzymatic domains allow tPA to function as both an enzyme and a cytokine. This study sought to determine whether cytokine activity is sufficient to rescue steroid-induced outflow facility reduction.

Methods: Outflow facility was measured in C57BL/6J mice following triamcinolone acetonide exposure and either transfection of the TM using adenoviral vectors, encoding for enzymatically active and inactive tPA, or administration of the respective proteins. Protein injections were also administered to tPA deficient (KO) and deficient (KO) mice to determine the potential to rescue reductions in outflow facility and determine downstream mechanisms. Gene expression of matrix metalloproteinases (, and ) was measured in angle ring tissues containing the TM.

Results: Enzymatically active and inactive tPA (either produced after TM transfection or after direct administration) were equally effective in attenuating steroid-induced outflow facility reduction in C57BL/6J mice. They were also equally effective in rescuing outflow reduction in KO mice and causing enhanced expression of matrix metalloproteinases. However, both enzymatically active and enzymatically inactive tPA did not improve outflow reduction in KO mice or increase the baseline outflow facility in naïve C57BL/6J mice.

Conclusions: tPA enzymatic activity is not necessary in the regulation of aqueous humor outflow. tPA can increase the expression of matrix metalloproteinases in a cytokine-mediated fashion. This cascade of events may eventually lead to extracellular matrix remodeling at the TM, which reverses outflow facility reduction caused by steroids.

Citing Articles

Gene therapy for glaucoma: Targeting key mechanisms.

Henderson J, OCallaghan J, Campbell M Vision Res. 2024; 225:108502.

PMID: 39423611 PMC: 11579448. DOI: 10.1016/j.visres.2024.108502.


Glucocorticoid-Induced Ocular Hypertension and Glaucoma.

Harvey D, Sugali C, Mao W Clin Ophthalmol. 2024; 18:481-505.

PMID: 38379915 PMC: 10878139. DOI: 10.2147/OPTH.S442749.

References
1.
OSullivan S, Medina C, Ledwidge M, Radomski M, Gilmer J . Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. Biochim Biophys Acta. 2013; 1843(3):603-17. DOI: 10.1016/j.bbamcr.2013.12.006. View

2.
Vassalli J, Sappino A, Belin D . The plasminogen activator/plasmin system. J Clin Invest. 1991; 88(4):1067-72. PMC: 295552. DOI: 10.1172/JCI115405. View

3.
Becker B . INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS. Invest Ophthalmol. 1965; 4:198-205. View

4.
Tane N, Dhar S, Roy S, Pinheiro A, Ohira A, Roy S . Effect of excess synthesis of extracellular matrix components by trabecular meshwork cells: possible consequence on aqueous outflow. Exp Eye Res. 2007; 84(5):832-42. DOI: 10.1016/j.exer.2007.01.002. View

5.
Acott T, Kelley M . Extracellular matrix in the trabecular meshwork. Exp Eye Res. 2008; 86(4):543-61. PMC: 2376254. DOI: 10.1016/j.exer.2008.01.013. View